Skip to search formSkip to main contentSkip to account menu

vismodegib

Known as: Vismodegibum 
An orally bioavailable small molecule with potential antineoplastic activity. Hedgehog antagonist GDC-0449 targets the Hedgehog signaling pathway… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

ErivedgeGDC-0449

Broader (1)

HhAntag691
NCIt Antineoplastic Agent Terminologyvismodegib 150 MG Oral Capsule

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Vismodegib treatment in a HIV positive patient on antiretroviral therapy
Observation: We report a case of a 64 year old man presented with a 3 year history of ulcerative basal cell carcinoma involving… 
Review
2018
Review
2018
Balancing early access with uncertainties in evidence for drugs authorized by prospective case series – systematic review of reimbursement decisions
To review clinical and cost‐effectiveness evidence underlying reimbursement decisions relating to drugs whose authorization… 
Highly Cited
2017
Highly Cited
2017
Corrigendum: Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma
Scientific Reports 7: Article number: 44079; published online: 09 March 2017; updated: 21 April 2017. In this Article, Monika… 
2017
2017
Smoothened antagonist GDC-0449 (Vismodegib) inhibits proliferation and triggers apoptosis in colon cancer cell lines.
The sonic hedgehog (Shh) pathway has been proven to be involved in embryonic development and cancer growth. GDC-0449, an… 
2016
2016
An unusual case of basal cell carcinoma of the vulva with lung metastases
2016
2016
Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study.
BACKGROUND MicroRNAs (miRNAs) have been identified as key players in posttranscriptional gene regulation and have a significant… 
2015
2015
Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
2015
2015
Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.
2013
2013
Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer…
4011 Background: The HH pathway is overexpressed in gastroesophageal (GE) tumors. Pre-clinically, HH inhibitors have demonstrated… 
2012
2012
Hedgehog hopes lifted by approval... and stung by failure
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)